The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Cradle
Provides generative AI software for engineering proteins and optimizing cellular factories.
What they do
Cradle develops generative AI tools that assist biologists in designing improved proteins and enzymes. The software predicts how amino acid sequences affect properties like stability and activity, helping industrial biotech and pharmaceutical teams reduce the number of wet-lab experiments required.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Delft, Netherlands
- Region
- Europe
- Founded
- 2022
- Total funding
- $33M raised
Notable investors: Index Ventures, Kindred Capital.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA